Tracey L Marsh
Overview
Explore the profile of Tracey L Marsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujiwara N, Lopez C, Marsh T, Raman I, Marquez C, Paul S, et al.
Gastroenterology
. 2024 Nov;
168(3):556-567.e7.
PMID: 39521255
Background & Aims: Hepatocellular carcinoma (HCC) risk stratification is an urgent unmet need for cost-effective HCC screening and early detection in patients with cirrhosis to improve poor HCC prognosis. Methods:...
2.
Marsh T, Parikh N, Roberts L, Schwartz M, Nguyen M, Befeler A, et al.
Gastroenterology
. 2024 Sep;
168(2):316-326.e6.
PMID: 39293548
Background & Aims: Better surveillance tests for hepatocellular carcinoma (HCC) are needed. The GALAD score (gender, age, α-fetoprotein [AFP] L3, AFP, and des-γ carboxyprothrombin) has been shown to have excellent...
3.
Zheng Y, Wagner P, Singal A, Hanash S, Srivastava S, Huang Y, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Sep;
33(9):1150-1157.
PMID: 39223980
Before implementing a biomarker in routine clinical care, it must demonstrate clinical utility by leading to clinical actions that positively affect patient-relevant outcomes. Randomly controlled early detection utility trials, especially...
4.
Yokoo T, Masaki N, Parikh N, Lane B, Feng Z, Mendiratta-Lala M, et al.
Radiology
. 2023 Jan;
307(2):e220917.
PMID: 36692401
Background Abbreviated MRI is a proposed paradigm shift for hepatocellular carcinoma (HCC) surveillance, but data on its performance are lacking for histopathologically confirmed early-stage HCC. Purpose To evaluate the sensitivity...
5.
Griffin J, Finney Rutten L, Zhu X, Feng Z, Rogers C, Marsh T, et al.
Contemp Clin Trials
. 2022 Jul;
119:106852.
PMID: 35842109
Background: Colorectal cancer (CRC) screening is underutilized despite evidence that screening improves survival. Since healthcare provider recommendation is a strong predictor of CRC screening completion, providers are encouraged to engage...
6.
Marsh T, Janes H, Pepe M
Biometrics
. 2019 Nov;
76(3):843-852.
PMID: 31732971
Referral strategies based on risk scores and medical tests are commonly proposed. Direct assessment of their clinical utility requires implementing the strategy and is not possible in the early phases...
7.
Kerr K, Marsh T, Janes H
Med Decis Making
. 2019 May;
39(5):491-492.
PMID: 31104561
No abstract available.
8.
Kerr K, Brown M, Marsh T, Janes H
Med Decis Making
. 2019 Jan;
39(2):86-90.
PMID: 30649998
Decision curves are a tool for evaluating the population impact of using a risk model for deciding whether to undergo some intervention, which might be a treatment to help prevent...
9.
Rutter C, Knudsen A, Marsh T, Doria-Rose V, Johnson E, Pabiniak C, et al.
Med Decis Making
. 2016 Jan;
36(5):604-14.
PMID: 26746432
Background: Microsimulation models synthesize evidence about disease processes and interventions, providing a method for predicting long-term benefits and harms of prevention, screening, and treatment strategies. Because models often require assumptions...